Skip to main content
Premium Trial:

Request an Annual Quote

Michael Olex, George Haas, Kate Bingham, and Paul Woloshin


Michael Olex has been named vice president, manufacturing at BioTrove.

Olex will oversee the construction of BioTrove’s 10,000 sq. ft. manufacturing facility for production of the first product in its Living Chip microfluidics platform, the company said. Prior to his appointment, Olex served as senior vice president, manufacturing and operations at US Genomics, and has held senior executive positions at PerSeptive Biosystems, now owned by Applied Biosystems.

Olex holds BS and MS degrees in electrical engineering from the University of Detroit and Cleveland State University, respectively, said BioTrove. He also earned an MBA from Case Western Reserve University.

George Haas has been appointed to the supervisory board of Ingenium Pharmaceuticals. Haas replaces Kate Bingham, general partner of Schroder Ventures Life Sciences, who stepped down at the end of 2003.

Most recently, Haas served as worldwide head of pharmaceutical development at Ciba-Geigy, where he was employed for 27 years.

He received his PhD in chemistry from the Federal Institute of Technology in Zurich, and completed his postdoctoral training at Cornell University. He also completed management training at Harvard Business School.

Paul Woloshin has been appointed executive director of the Oregon Biosciences Association. Woloshin will lead OBA in its mission to support and expand Oregon’s bioscience community, both commercial and academic, the organization said.

Woloshin most recently held the position of director of finance and administration for the Oregon Health and Science University Research Division.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.